Skip to main content
BIPSX logo

ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) Fund Overview

Educational signal · not a buy or sell recommendation · How to read this

$47.00 -$0.05 (-0.11%)
P/E Ratio: 2.03|

P/E 2.03 means the share price is 2.03 times one year of earnings per share. Beta 1.62: the stock has moved about 62% more than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) trades at $47.00. Sector: Financials.

Price as of · Last analyzed: Jun 15, 2026
ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) is a leveraged mutual fund designed to deliver daily investment results corresponding to twice the daily performance of the S&P Biotechnology Select Industry Index. The fund employs a concentrated investment strategy within the U.S. biotechnology sector, making its performance highly sensitive to industry trends and market volatility.

Analyst Coverage for BIPSX: BIPSX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

▶ Watch the BIPSX film Every key number, told as a short cinematic story — just press play. ~2 min

ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) Financial Services Profile

HeadquartersBethesda, US
IPO Year2000

ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) is a specialized mutual fund offering 2x leveraged daily exposure to the U.S. biotechnology sector, tracking the S&P Biotechnology Select Industry Index. Its concentrated investment approach aims to amplify returns in a rising market, while also increasing sensitivity to sector-specific downturns and overall market volatility, positioning it for investors seeking aggressive, short-term tactical exposure.

Data Provenance | Financial Data Quantitative Analysis Analysis: Jun 15, 2026

What Is the Investment Thesis for BIPSX?

AI-written as of Jun 15, 2026 — figures and tone reflect the data available then, not today's score.

ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) offers a unique investment proposition for sophisticated investors seeking amplified daily returns tied to the U.S. biotechnology sector. The fund's core value driver is its leveraged structure, aiming to deliver twice (2x) the daily performance of the S&P Biotechnology Select Industry Index. This leverage acts as a significant catalyst in periods of strong, sustained upward momentum within the biotechnology industry, potentially generating substantial daily gains. However, this also represents its primary risk factor, as the same leverage magnifies losses during periods of market volatility or sector-specific downturns. The fund's concentrated investment approach, focusing exclusively on the biotechnology sector, means its performance is directly and heavily influenced by industry-specific developments, regulatory changes, and scientific breakthroughs. Investors must closely monitor the underlying index's performance, broader biotechnology industry trends, and the fund's expense ratio, as these factors directly impact net returns. BIPSX is positioned as a tactical tool for short-term exposure rather than a long-term core holding, given its daily rebalancing and compounding effects over extended periods.

Based on FMP financials and quantitative analysis

BIPSX Key Highlights

AI-written as of Jun 15, 2026 — figures and tone reflect the data available then, not today's score.

Market Capitalization of $0.15 billion, reflecting its niche focus within the broader asset management landscape.

  • Beta of 1.62, indicating significantly higher volatility and market sensitivity compared to the overall market.
  • Designed to deliver 2x daily leveraged returns corresponding to the S&P Biotechnology Select Industry Index, amplifying both gains and losses.
  • Employs a concentrated investment strategy, focusing exclusively on the U.S. biotechnology sector without broad diversification.
  • Does not pay a dividend, consistent with its objective of capital appreciation through leveraged sector exposure.

Who Are BIPSX's Competitors?

BIPSX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
BLK BlackRock, Inc. $1066.45 +0.64% $164B 51 5-pillar
BX Blackstone Inc. $111.64 -0.09% $136B 68 5-pillar
APOS Apollo Global Management, Inc. $25.59 0.00% $74.8B 56 5-pillar
BAM Brookfield Asset Management $44.73 -0.27% $71.6B 57 5-pillar
AMP Ameriprise Financial, Inc. $494.94 +0.82% $44.4B 77 5-pillar
ARES Ares Management Corporation $117.13 -0.36% $38.5B 57 5-pillar
TROW T. Rowe Price Group, Inc. $103.93 -0.66% $22.4B 80 5-pillar
ATHS Athene Holding Ltd. $23.59 +0.34% $18.8B 56 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BIPSX's Key Strengths?

Provides 2x leveraged daily exposure to the U.S. biotechnology sector, amplifying potential gains in a rising market.

  • Offers targeted, concentrated exposure to a high-growth, innovative industry.
  • Managed by an adviser with expertise in leveraged and sector-specific fund strategies.
  • Can be a powerful tool for short-term tactical trading strategies.

What Are BIPSX's Weaknesses?

Leverage magnifies losses, making it highly sensitive to biotechnology sector downturns and market volatility.

  • Concentrated investment approach means performance is solely dependent on the biotechnology industry, lacking diversification.
  • Daily rebalancing can lead to performance drag and compounding effects over longer holding periods.
  • Potentially higher expense ratios compared to unleveraged or broadly diversified funds.

What Are the Key Risks for BIPSX?

Magnified losses due to the fund's 2x leveraged structure, meaning a 1% decline in the underlying index results in an approximate 2% decline for the fund.

  • High sensitivity to market volatility and downturns in the biotechnology sector, which can lead to significant and rapid capital erosion.
  • The concentrated investment approach exposes the fund to specific risks inherent in the biotechnology industry, such as regulatory hurdles, failed clinical trials, and patent expirations.
  • Performance deviation from the stated objective over periods longer than one day due to the effects of daily compounding and rebalancing.
  • Adverse changes in the regulatory environment for drug development or pricing policies could negatively impact the profitability and growth prospects of biotechnology companies.

What Threats Does BIPSX Face?

  • Significant downturns or prolonged stagnation in the biotechnology sector, leading to magnified losses.
  • High market volatility, which can erode returns due to the effects of daily rebalancing and compounding.
  • Regulatory changes impacting the biotechnology industry or the use of leveraged investment products.
  • Competition from other leveraged ETFs or mutual funds offering similar or alternative sector exposure.

What Are BIPSX's Competitive Advantages?

  • Specialized 2x leveraged daily exposure to the S&P Biotechnology Select Industry Index, a niche offering within the mutual fund landscape.
  • Expertise of the fund's adviser in managing leveraged and sector-specific strategies to track the target index.
  • Established brand recognition within the ProFunds family, known for its range of geared and inverse funds.
  • Operational infrastructure and systems required to manage daily rebalancing and derivative instruments for leveraged performance.

What Does BIPSX Do?

ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) operates within the asset management industry, offering a specialized investment vehicle designed to provide leveraged exposure to the U.S. biotechnology sector. The fund's core investment strategy involves meticulously allocating capital across various financial instruments, which are carefully selected by its adviser. The primary objective is to achieve daily investment results, before fees and expenses, that correspond to twice (2x) the daily performance of a specific benchmark: the S&P Biotechnology Select Industry Index. This index is engineered to measure the performance of select companies operating within the U.S. biotechnology segment of the equity market. The fund's approach is characterized by its concentrated investment methodology, meaning it deliberately avoids broad diversification. This focused strategy implies that the fund's performance is intrinsically and heavily reliant on the health, growth, and specific trends within the biotechnology industry. While this leveraged and concentrated structure can significantly amplify gains during periods of sector growth, it concurrently magnifies potential losses during downturns, making BIPSX highly sensitive to market volatility and adverse developments within the biotechnology sector. Investors considering BIPSX typically seek aggressive, short-term tactical exposure to the biotechnology industry, acknowledging the inherent risks associated with its leveraged and non-diversified nature. The fund's headquarters are located in Bethesda, US, operating under the broader ProFunds umbrella, which specializes in offering a range of geared and inverse funds.

What Products and Services Does BIPSX Offer?

  • Seeks to achieve daily investment results that correspond to twice (2x) the daily performance of the S&P Biotechnology Select Industry Index.
  • Invests primarily in financial instruments that provide exposure to companies within the U.S. biotechnology sector.
  • Employs a concentrated investment approach, meaning it is not broadly diversified across multiple sectors or asset classes.
  • Utilizes various financial instruments, including derivatives, to achieve its leveraged daily objective.
  • Managed by an adviser who selects the specific financial instruments for capital allocation.
  • Offers investors a way to gain magnified, short-term exposure to the performance of the biotechnology industry.

How Does BIPSX Make Money?

  • Generates revenue through management fees charged to fund shareholders for its advisory and operational services.
  • Aims to achieve its investment objective by strategically investing in a portfolio of financial instruments, including equity securities and derivatives.
  • Relies on the expertise of its investment adviser to select and manage the fund's holdings to track the target index with leverage.
  • Operates as a mutual fund, attracting capital from investors seeking specific leveraged exposure to the biotechnology sector.

What Industry Does BIPSX Operate In?

ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) operates within the highly specialized segment of the asset management industry, specifically focusing on leveraged and sector-specific funds. The broader asset management industry is characterized by intense competition, evolving regulatory landscapes, and a constant demand for innovative investment products. BIPSX distinguishes itself by offering targeted, leveraged exposure to the U.S. biotechnology sector, a segment known for its high growth potential, innovation cycles, and inherent volatility. Market trends indicate a growing interest in thematic and sector-specific investments, as well as sophisticated tools like leveraged funds for tactical trading. However, these products cater to a specific investor demographic due to their amplified risk profiles. BIPSX's position is that of a specialized instrument for investors who have a strong conviction in the short-term direction of the biotechnology industry and are prepared for magnified market movements.

Who Are BIPSX's Key Customers?

  • Sophisticated individual investors seeking leveraged, short-term exposure to the biotechnology sector.
  • Active traders looking to capitalize on daily movements within the S&P Biotechnology Select Industry Index.
  • Institutional investors and hedge funds employing tactical allocation strategies.
  • Investors with a high-risk tolerance who understand the implications of leveraged and concentrated investments.
Model self-rating on this text: 79% (not a measure of the evidence) Updated: Jun 15, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage
  • ● This is a fund, not an operating company

MoonshotScore History

Recorded daily since 2026-08-23 · 41 snapshots

2026-08-23 47
2026-08-31 47
2026-09-08 47
2026-09-16 47
2026-09-24 47
2026-10-04 47

What changed?

The score has stayed at 47.

Over the same 30 days the stock moved -9.5%.

BIPSX Financials

Bull Case vs Bear Case

Bull Case

  • Provides 2x leveraged daily exposure to the U.S. biotechnology sector, amplifying potential gains in a rising market.
  • Offers targeted, concentrated exposure to a high-growth, innovative industry.
  • Managed by an adviser with expertise in leveraged and sector-specific fund strategies.
  • Can be a powerful tool for short-term tactical trading strategies.

Bear Case

  • Leverage magnifies losses, making it highly sensitive to biotechnology sector downturns and market volatility.
  • Concentrated investment approach means performance is solely dependent on the biotechnology industry, lacking diversification.
  • Daily rebalancing can lead to performance drag and compounding effects over longer holding periods.
  • Potentially higher expense ratios compared to unleveraged or broadly diversified funds.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026

BIPSX Latest News

No recent news available for BIPSX.

BIPSX Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BIPSX.

Price Targets

Wall Street price target analysis for BIPSX.

BIPSX MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BIPSX; grades run from A+ (80-100) to F (below 30).

BIPSX Financials Stock FAQ

What does ProFunds Biotechnology UltraSector Fund Service Class do?

ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) is an investment fund designed to provide leveraged exposure to the U.S. biotechnology sector.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

MoonshotScore is not published for this security.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based solely on the provided source data. No external research was conducted.
  • Growth opportunities are framed around the fund's ability to capitalize on sector trends, as it is an investment product rather than an operating company with traditional growth strategies.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis